Lessons from the Eye: Stem Cell Therapies Advancing Regenerative Medicine on April 27, 2026 Clinical Trials Disorder of eye Injury of cornea Macular degeneration Regenerative Medicine Retinitis Pigmentosa Stem Cell Therapy +
Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market on September 17, 2025 Ang2 Biosciences Clinical Trials Disorder of eye Macular edema due to diabetes mellitus Ollin OLN324 Roche (company) Vabysmo Vascular Endothelial Growth Factor A Wet AMD +
Roche Pledges Nearly $300M to Establish New Vabysmo Production Plant in China on May 13, 2025 biopharmaceutical manufacturing China Disorder of eye green energy Investments localization plant construction Roche (company) Shanghai Vabysmo +
Beacon's rare eye disease gene therapy signals vision function improvements in early phase 2 data on May 07, 2025 DAWN Disorder of eye gene therapy laru-zova Phase 2 trial Vision XLRP +
J&J's $130M gene therapy bet flunks rare retinal disease trial on May 06, 2025 bota-vec Disorder of eye Failure (biologic function) gene therapy Infrequent Investments Johnson and Johnson loss treatment Phase 3 Vision X-linked retinitis pigmentosa +